Skip to content

Total Infectome Characterization of Eye Infections

Total Infectome Characterization of Eye Infections: a Metagenomic Sequencing Based Observational Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06775808
Enrollment
200
Registered
2025-01-15
Start date
2024-12-25
Completion date
2026-12-31
Last updated
2025-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosis, Eye Infections

Keywords

infectome, metagenomic sequencing

Brief summary

Multiple pathogens can cause eye infection. In recent years, emerging and resurging viral infections represent an important public health problem. Many emerging viruses cause infectious diseases involving ophthalmic manifestations, including Mpox virus, Zika, Ebola, and SARS-CoV-2. Broad and unbiased pathogen surveillance is essential, so we design this unbiased metagenomic sequencing based study to investigate the total infectome of eye infections. The study is historical and prospective in design.

Detailed description

This is an investigator-initiated observational study to describe the total infectome of eye infections using metagenomic sequencing. The eye infections, including acute conjunctivitis, keratitis, uveitis, and endophthalmitis, are diagnosed by experienced ophthalmologists according to routine clinical exams. For the collection of additional biological samples apart from the diagnosis and treatment process, written informed consent is required from the eligible subjects or their legal guardians at the recruitment time is required. The application for exemption of informed consent has been made for using clinical surplus samples. After completing informed consent, subjects will be sampled, and their clinical information will be collected. Biospecimens, including conjunctival sac swabs (1 swab for each involving eye), or intraocular fluid (more than 100μl), will be collected for metagenomic sequencing using the Illumina NovaSeq X Plus platform. The clinical information of participants will be collated from electronic medical record information system, including (1) demographic characteristics: age, sex, comorbidities; (2) laboratory examination: blood routine test, immune inflammatory factors, clinical microbiology examination (PCR, serological examination, culture, etc.); (3) imaging examination: anterior segment photograph, corneal endothelial cell examination, corneal confocal microscopy, fundus photograph. Meta-transcriptomic analysis of the ocular samples will be conducted to identify viruses, bacteria, fungi and parasites. The abundance of pathogens is indicated as the RPKM (i.e. Reads Per Million divided by the length of the reference genome, measured in kilobases). Eligible participants will be recruited consecutively between August, 2024 and December, 2026 in Department of Ophthalmology, Shanghai General Hospital. The total study duration is expected to be two years from the first subject enrolled to the final analysis.

Interventions

None listed

Sponsors

Shanghai Fourth People's Hospital Tongji University
CollaboratorOTHER
The Central Hospital of Huanggang
CollaboratorOTHER
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Patients with a clinical diagnosis of one or more types of eye infections (including acute conjunctivitis, keratitis, uveitis, and endophthalmitis). 2. Biological samples has been collected for clinical microbiological examination, or consented to participate in this study.

Exclusion criteria

1\. Patients who have no historically clinical surplus specimens.

Design outcomes

Primary

MeasureTime frameDescription
The pathogen profilethrough study completion, an average of 2 yearThe bacteria, fungi, viruses, and parasites identified through metagenomic techniques in ocular samples.

Secondary

MeasureTime frameDescription
Microbial abundancethrough study completion, an average of 2 yearThe pathogen abundance is measure by the RPKM (i.e. Reads Per Million divided by the length of the reference genome, measured in kilobases).

Countries

China

Contacts

Primary ContactMei Kang, MPH
mei.kang@shgh.cn021-36126064

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026